EA201800477A1 - DRUG FOR TREATMENT OF ONCOLOGICAL DISEASES - Google Patents

DRUG FOR TREATMENT OF ONCOLOGICAL DISEASES

Info

Publication number
EA201800477A1
EA201800477A1 EA201800477A EA201800477A EA201800477A1 EA 201800477 A1 EA201800477 A1 EA 201800477A1 EA 201800477 A EA201800477 A EA 201800477A EA 201800477 A EA201800477 A EA 201800477A EA 201800477 A1 EA201800477 A1 EA 201800477A1
Authority
EA
Eurasian Patent Office
Prior art keywords
drug
cytostatics
particles
targeted delivery
tumor tissues
Prior art date
Application number
EA201800477A
Other languages
Russian (ru)
Inventor
Елена Дмитриевна НИКОЛЬСКАЯ
Оксана Геннадьевна ТЕРЕЩЕНКО
Ольга Александровна ЖУНИНА
Борис Игоревич КРУГЛЫЙ
Никита Григорьевич ЯББАРОВ
Евгений Сергеевич СЕВЕРИН
Original Assignee
Ооо "Нпк Альфа-Онкотехнологии"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ооо "Нпк Альфа-Онкотехнологии" filed Critical Ооо "Нпк Альфа-Онкотехнологии"
Priority to EA201800477A priority Critical patent/EA201800477A1/en
Priority to PCT/RU2018/000674 priority patent/WO2020046163A1/en
Publication of EA201800477A1 publication Critical patent/EA201800477A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение описывает новый противоопухолевый препарат, представляющий собой стабильные наночастицы из биодеградирующего полимера, включающие два цитостатических агента с различными механизмами действия и векторную молекулу для адресной доставки частиц в опухолевые ткани. Предпочтительно в лекарственную композицию также входят поверхностно-активное вещество и криопротектор. В качестве цитостатиков используются винкристин и метотрексат, в качестве векторной молекулы для адресной доставки частиц в опухолевые ткани - C-концевой домен альфа-фетопротеина. Изобретение обеспечивает существенное повышение эффективности и безопасности указанных цитостатиков. Лекарственное средство представляет собой образец готовой формы препарата, который по параметрам растворения, однородности, пирогенности, уровню эндобактериальных токсинов, стабильности, стерильности соответствует стандартам использования стерильных лекарственных форм для медицинского применения у человека. Показаниями к применению препарата могут являться острый и хронический миелоидный лейкоз, лимфобластный лейкоз и другие онкологические заболевания мягких тканей.The invention describes a new antitumor drug, which is a stable nanoparticles of a biodegradable polymer, including two cytostatic agents with different mechanisms of action and a vector molecule for targeted delivery of particles to tumor tissues. Preferably, the surfactant and cryoprotectant are also included in the pharmaceutical composition. Vincristine and methotrexate are used as cytostatics, and the C-terminal domain of alpha-fetoprotein is used as a vector molecule for targeted delivery of particles to tumor tissues. The invention provides a significant increase in the efficiency and safety of these cytostatics. The drug is a sample of the finished form of the drug, which according to the parameters of dissolution, uniformity, pyrogenicity, the level of endobacterial toxins, stability, sterility meets the standards for the use of sterile dosage forms for medical use in humans. Indications for use of the drug may be acute and chronic myeloid leukemia, lymphoblastic leukemia and other oncological diseases of soft tissues.

EA201800477A 2018-08-28 2018-08-28 DRUG FOR TREATMENT OF ONCOLOGICAL DISEASES EA201800477A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA201800477A EA201800477A1 (en) 2018-08-28 2018-08-28 DRUG FOR TREATMENT OF ONCOLOGICAL DISEASES
PCT/RU2018/000674 WO2020046163A1 (en) 2018-08-28 2018-10-11 Preparation for treating oncological diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201800477A EA201800477A1 (en) 2018-08-28 2018-08-28 DRUG FOR TREATMENT OF ONCOLOGICAL DISEASES

Publications (1)

Publication Number Publication Date
EA201800477A1 true EA201800477A1 (en) 2020-02-28

Family

ID=69636676

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201800477A EA201800477A1 (en) 2018-08-28 2018-08-28 DRUG FOR TREATMENT OF ONCOLOGICAL DISEASES

Country Status (2)

Country Link
EA (1) EA201800477A1 (en)
WO (1) WO2020046163A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2285537C1 (en) * 2005-04-05 2006-10-20 Автономная некоммерческая организация "Институт молекулярной диагностики (АНО "ИнМоДи") Antitumor peptide preparation based on alpha-fetoprotein fragment, its conjugate, pharmaceutical composition and method for treatment of hormone-dependent tumors
ES2647538T3 (en) * 2007-09-28 2017-12-22 Pfizer Inc. Addressing to cancer cells using nanoparticles
RU2451509C1 (en) * 2011-03-31 2012-05-27 Автономная некоммерческая организация "Институт Молекулярной Диагностики" (АНО "ИнМоДи) Anti-tumour preparation

Also Published As

Publication number Publication date
WO2020046163A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
EA201890159A1 (en) METHODS OF TREATMENT OF HEMATOLOGICAL MALIGNANT NATIONAL FORMATION WITH THE HELP OF COMBINED THERAPY BY mTOR INHIBITOR IN THE FORM OF NANOPARTICLES
CY1119490T1 (en) PYRAZOLOPYROLIDINE PRODUCTS AND THEIR USE IN PATIENT TREATMENT
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2020001513A (en) Clec9a binding agents and use thereof.
MX2019013701A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents.
CY1121698T1 (en) LIQUID INHALATION PREPARATION CONTAINING RPL554
NI201000145A (en) DERIVATIVES OF IMIDAZINE - [1, 2-b] - PYRIDAZINE FOR THE TREATMENT OF DISEASE MEDIATED BY TYROSINE KINASE C-MET.
MX2019012884A (en) Combination therapy.
MX2017016134A (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease.
EA201490254A1 (en) COMBINED TREATMENT OF HEPATITIS C
UY32739A (en) COMBINATIONS OF CHEMOTHERAPIC AGENTS AND ANTAGONISTS DLL4 AND ITS USES IN CANCER THERAPY
EA201691789A1 (en) PHARMACEUTICAL COMPOSITIONS AND SALTS OF 1,2,4-OXADIAZOLBENZOIC ACID
BR112015006929A2 (en) biodegradable drug delivery systems for sustained protein release
CO2023018231A2 (en) Novel therapeutic administration residues and uses of these
CY1122899T1 (en) AQUEOUS FORMULATION INCLUDING PARACETAMOL AND IBUPROPHEN
EA201691570A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING DIAMINO-HETEROCYCLIC CARBOXAMIDE COMPOUND AS AN ACTIVE INGREDIENT
AR090972A1 (en) METHOD TO TREAT AMD IN ANTI-VEGF THERAPY-RESISTANT PATIENTS
EA201490721A1 (en) Drug for the treatment of diseases of the anterior chamber of the eye, including rebamipid and tear-retaining agent
CY1111482T1 (en) COMBINATION AZD2171 AND PERMETRAXED
MX2018010223A (en) Combination therapy for treatment of ovarian cancer.
CO2022007814A2 (en) Tyk2 pseudokinase ligands
MX2023010711A (en) Phenalkylamines and methods of making and using the same.
EA201600469A1 (en) PHARMACEUTICAL PREPARATION FOR PREVENTION AND TREATMENT OF PROGRESSIVE PATTERNS
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS